BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10921093)

  • 1. [Clinical study of childhood acute myelogenous leukemia].
    Zhao X; Hu Y; Zang Y
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):6-9. PubMed ID: 10921093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status of complete remission rate of acute leukemia in Shanghai].
    Shanghai Leukemia Cooperative Group Shanghai 200040 China
    Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):17-9. PubMed ID: 11876954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Childhood acute myeloblastic leukemias. Report of 21 cases].
    Laatiri MA; Chehata S; Amouri A; Bouaouina N; Chatti S; Saad A; Ennabli S
    Tunis Med; 2000 Mar; 78(3):167-71. PubMed ID: 11026819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
    Kobayashi R; Tawa A; Hanada R; Horibe K; Tsuchida M; Tsukimoto I;
    Pediatr Blood Cancer; 2007 Apr; 48(4):393-8. PubMed ID: 16550530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
    de Botton S; Coiteux V; Chevret S; Rayon C; Vilmer E; Sanz M; de La Serna J; Philippe N; Baruchel A; Leverger G; Robert A; San Miguel J; Conde E; Sotto JJ; Bordessoule D; Fegueux N; Fey M; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2004 Apr; 22(8):1404-12. PubMed ID: 15084614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
    Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis.
    Inaba H; Fan Y; Pounds S; Geiger TL; Rubnitz JE; Ribeiro RC; Pui CH; Razzouk BI
    Cancer; 2008 Aug; 113(3):522-9. PubMed ID: 18484648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biologic features of 688 cases of childhood acute leukemia-a single centre retrospective study].
    Guo Y; Chen YM; Zou Y; Chen XJ; Zhang L; Wang SC; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Oct; 11(10):793-6. PubMed ID: 19849934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
    Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
    J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance].
    Zhang JB; Sun Y; Dong J; Liu LX; Ning F
    Ai Zheng; 2005 Aug; 24(8):1015-7. PubMed ID: 16086885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
    Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improved results of treatment in 30 cases of acute nonlymphocytic leukemia in childhood].
    Imashuku S; Arakawa S; Todo S; Esumi N; Tsunamoto K; Hashida T; Morioka Y; Hibi S; Nagai T; Fujiwara F
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2581-7. PubMed ID: 3740859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.